AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06678685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: .spironolactone
Description: In the first week, the starting dose is 2mg/Kg per body weight once a day, taken with food at lunch every day, and subsequently adjusted according to the situation. If the patient's serum potassium is ≤5.0 mEq/L and the patient's serum creatinine is ≤2.5 mg/dL, treatment should be initiated with 25 mg spironolactone once daily. Increased to 100mg after remission. If the results are not obvious in the first month, increase the drug dose to 3mg/Kg.
Study NCT05920330 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nasal Plug
Description: Please see the arm description for details.
Study NCT05319730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: 4 mg/kg IV infusion on Days 1, 15, and 29 of each 42-day cycle.
Study NCT05319730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Administered per product label.
Study NCT05319730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H2 Receptor Antagonist
Description: Administered per product label.
Study NCT05319730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (or equivalent)
Description: Administered per product label.
Study NCT05319730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (or equivalent)
Description: Administered per product label.
Study NCT06623630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Standard of care
Study NCT06623630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene Autoleucel
Description: Standard of care
Study NCT06623630 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Radiation doses delivered to the entire body
Study NCT04701242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10mg
Description: comparing upfront use of Ezetimibe (added to high intensity statins) after acute myocardial infarction versus selective Ezetimibe initiation to those failing to achieve LDL-C targets when assessed in follow up visit.
Study NCT06303297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REFLEXOLOGY
Description: will receive foot and hand reflexology and stretching. The researcher will administer foot and hand reflexology to the participant for a period of 3 weeks this last for a duration of 10 min on each hand and foot with total duration of 40 minutes. Foot reflexology include general foot massage, including the foot rotation, Achilles stretching, and the foot extension and stretching, will be performed for a minute on each foot. In the right foot, the bottom of the heel will be kept with the left hand, and the metatarsal arch of the same foot will be held with the other hand. Then, the foot will be rotated clockwise and counter clockwise three times each direction. The same technique will be performed on the left foot. On hand lubricated with moisturizer to the dorsal and plantar surface and apply pressure on for 10 minutes. Noninvasive and safe complementary therapy that involves a direct pressure on specific body points connecting specific organs.
Study NCT06303297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GENERALIZED STRETCHING
Description: will receive Stretching of upper and lower limbs. The stretching program lasts for 3 weeks with 60 min of stretching session 3 times a week. Extension of body include shoulder extension, torso rotation, hip extension, calf stretching (ankle pumps). ten stretches of 30 s each, with 15 s of rest between each stretch
Study NCT06696716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ONO-4059
Description: Tirabrutinib is a Bruton's Tyrosine Kinase Inhibitor. Tirabrutinib will be administered orally at a dose of 80 mg once daily after a meal (breakfast, lunch, or dinner).
Study NCT06696716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-4059 placebo
Description: Placebo will be administered orally once daily after a meal (breakfast, lunch, or dinner).
Study NCT06699030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Functional fatty acids
Description: Days 1-3: Oral Administration of functional fatty acids Days 4-6: Oral Administration of functional fatty acids
Study NCT06699030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Days 1-3: Placebo Days 4-6: Oral Administration of functional fatty acids
Study NCT06712329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave therapy
Description: ESWT (Inceler Medical, Modus Focused ESWT, Turkey) was conducted by a single investigator in accordance with a standardised protocol. The patients were positioned prone on the examination table, with the affected limb placed in a supported position. The focused shockwave was applied in a circular motion along the insertion site of the plantar fascia and over the plantar fascia itself. The participants received 1,800 to 2,000 focused shock waves (0.15-0.25 mJ/mm² session with a frequency of 3-4 Hz). The frequency of the pulses was increased in a gradual manner, in accordance with the maximum tolerable degree of pain for each patient. A minimum dose of 1,000 mJ/mm² was administered. The ESWT was conducted in three sessions, with a two-week interval between each session.
Study NCT06712329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: The solution employed for dextrose prolotherapy comprised 1.5 ml of 30% dextrose and 1.5 ml of 0.9% isotonic sodium chloride solution, resulting in a total of 3 ml of 15% dextrose solution. . All procedures were conducted by the same investigator. A dextrose solution was infused into the centre and around the damaged area using a peppering technique. Following the procedure, patients were advised to remain in a supine position with their feet restrained for a period of 15 minutes.. Prolotherapy was repeated on three occasions, with each session occurring at a two-week interval
Study NCT06713005 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: suprascapular nerve block and 4 mins Pulsed radiofreuency application to suprascapular nerve
Description: suprascapular nerve pulsed rf
Study NCT06713005 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: suprascapular nerve block and 9 mins Pulsed radiofreuency application to suprascapular nerve
Description: suprascapular nerve block and 4 mins Pulsed radiofreuency application to suprascapular nerve
Study NCT06731530 — intervention group
Intervention type: DEVICE
Intervention: Pentacam-AXL
Description: Pentacam-AXL (Oculus, Wetzlar, Germany)
Study NCT06731530 — intervention group
Intervention type: DEVICE
Intervention: HD Analyzer
Description: HD Analyzer (Visiometrics, Terassa, Spain, Keeler)
Study NCT05668884 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
Description: Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
Study NCT06341101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril
Description: In case of side effects Perindopril will be replaced by Valsartan
Study NCT04882384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular Nerve Group Block
Description: This will be a peripheral nerve block.
Study NCT06378580 — intervention group
Intervention type: DRUG
Intervention: Surufatinib combine immune checkpoint inhibitor
Description: Before drug use demographics, blood markers, pathology information# and enhanced CT features.~Chemotherapy regimens that were combined with surufatinib included AG or FOLFIRINOX regimens. The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxalip
Study NCT06378580 — intervention group
Intervention type: DRUG
Intervention: AG/FOLFIRINOX
Description: Before drug use demographics, blood markers, pathology information# and enhanced CT features.~The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxaliplatin (85 mg/m2), irinotecan (180 mg/m2), leucovorin (400 mg/m2), and 5-fluorouracil (400 mg/m2 bolus, 2400 mg/m2 continuous intravenous infusion for 46 hours) every 14 days. Both the AG and FOLFIRINOX regimens required completion of 6 cycles or until disease progression or unacceptable toxicity.
Study NCT05622695 — intervention group
Intervention type: DEVICE
Intervention: catheterization
Description: Swan-Ganz catheterization (also called right heart catheterization or pulmonary artery catheterization) is the passing of a thin tube (catheter) into the right side of the heart and the arteries leading to the lungs. It is done to monitor the heart's function and blood flow and pressures in and around the heart.
Study NCT04555343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 1gm instilled instravesically
Study NCT04007926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise programme
Description: Participants will start with 3 x 20 minute exercise sessions in the first week, building up to 5 x 60 minutes of exercise by weeks 9-12 of the intervention, at an intensity of 65-80% of predicted maximum heart rate.
Study NCT04007926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise programme
Description: Participants will undertake two supervised sessions per week. The exercises performed during each session will consist of leg press, calf press, leg extension, leg curl, chest press, shoulder press, lateral pull down and seated row. Exercises will be performed at 60-80% 1RM. In weeks 1-2 participants will perform, during each session, a single set of 5-10 repetitions of each exercise (tiring but comfortably achievable) to ensure they are comfortable with the exercises and are performing these in the correct form. In weeks 3-4 participants will perform, during each session, two sets of each exercise to voluntary muscular failure - defined as not being able to perform single another repetition. In weeks 5-12 this will progress to 3 sets of each exercise to voluntary muscular failure, in each session.
Study NCT06506682 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constraint Induced Movement Therapy
Description: CIMT is an intensive upper limb therapy for children with unilateral (one sided) cerebral palsy where the child wears a constraint (splint or mit) on their dominant hand so that they use the involved (weaker) side to do activities
Study NCT06506682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CIMT + VR
Description: Participants in the CIMT+VR group of this study protocol will do everything the CIMT group does PLUS will utilize at least 4 of the following VR technologies each day of intervention: FitMi, Tyromotion Pablo® UpperExtremity, Hocoma Armeo® Spring Pediatric, Nintendo Wii, and Parrot Drone.
Study NCT05338996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iENGAGE for PrEP
Description: This intervention originally developed for people living with HIV (PLWH), is designed to promote engagement, retention, and adherence to treatment by addressing the social determinants of health that often act as barrier to remaining in care and achieving viral suppression. Based on our experience with this intervention we believe that it is well suited to similarly promote engagement, retention, and utilization of PrEP care among our proposed target population of WOC by a) removing barriers to care and b) addressing unmet needs by providing c) point-to-point linkage to care services delivered by multi-disciplinary teams of individuals within or outside of the health facility, and d) the use of telehealth visits to facilitate engagement in care and improve health visit attendance. The original iENGAGE is a 4-session, in-clinic behavioral intervention.
Study NCT05638204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suicidal Crisis Intervention (SCI)
Description: This study's experimental condition consisted of the Suicidal Crisis Intervention (SCI), developed by the Flemish Centre of Expertise of Suicide prevention. The SCI aims to provide tools for dealing with future suicidal crises for people after a suicidal crisis or suicide attempt. The intervention attempts to provide insight into the suicidal crisis by giving suicidality meaning within the life history. It aims to increase motivation for specialized care and therefore facilitate continuity of care. In addition, the method also wants to involve the close relative(s) of the suicidal person in the treatment. The SCI offers care providers a clear structure and handles to do this within a short period of time (4 sessions). Within the SCI are a number of crucial elements: the therapeutic relationship, involving loved ones, person-centred care, the Integrated Explanatory Model for Suicidal Behavior (Van Heeringen, 2007), the safety plan (Stanley \& Brown, 2012) and continuity of care.
Study NCT05487352 — intervention group
Intervention type: OTHER
Intervention: hyperglycemia exposure in the first trimester
Description: The exposure means the hyperglycemia identified by the 75g oral glucose tolerance test before the 14 weeks of gestation
Study NCT06731530 — intervention group
Intervention type: DEVICE
Intervention: Corvis ST
Description: Corvis ST (Oculus, Germany)
Study NCT06731530 — intervention group
Intervention type: DEVICE
Intervention: OCT-A Angiovue
Description: OCT-A Angiovue (Optovue, Inc., Fremont, California, USA)
Study NCT06731530 — intervention group
Intervention type: DEVICE
Intervention: IOLMaster V.5.4
Description: IOLMaster V.5.4 (Carl Zeiss., Meditec)
Study NCT05747287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microcatheter
Description: supports the insertion of the guide wire，exchange of the guide wire and the delivery of contrast media
Study NCT06731530 — intervention group
Intervention type: DEVICE
Intervention: Topcon SP-1P
Description: Topcon SP-1P (Topcon Medical Inc., Tokyo, Japan)
Study NCT06609928 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FOLR1 CAR T-cells
Description: Given IV
Study NCT06609928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo CSF and blood sample collection
Study NCT06609928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT06609928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT06609928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT06609928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06731530 — intervention group
Intervention type: OTHER
Intervention: BCVA (ETDRS), Slit lamp examination, Goldmann Applanation Tonometry, Fundus examination
Description: BCVA (ETDRS), Slit lamp examination, Goldmann Applanation Tonometry, Fundus Examination
Study NCT06741254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Ball
Description: During the NST procedure (average 20-30 minutes), the pregnant woman will lie on her left side. A stress ball will be placed in the right hand of the pregnant woman. The pregnant woman will be instructed to squeeze the stress ball for 2-3 seconds and then relax the hand and arm. This process will be repeated throughout the NST.
Study NCT06741176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The research data will be collected with mothers whose babies are in the NICU. Information about the research will be given to mothers who come to leave milk for their babies and the research will be conducted with those who agree to participate. All surveys will be pre-tested on the mothers without randomization and the group they are in will be determined by randomization. The mothers in the experimental group will be asked to write messages to their babies on the milk bags they bring in the mornings for 3 days. They will be asked to write on the paper attached to the milk bag what they want to tell their baby that the investigators will read the message to them and to return it every morning. The post-test of all surveys will be conducted at the end of the 3rd day.
Study NCT06609928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT06741176 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The research data will be collected with mothers whose babies are in the NICU. Information about the research will be given to mothers who come to leave milk for their babies and the research will be conducted with those who agree to participate. All surveys will be pre-tested on the mothers without randomization and the group they are in will be determined by randomization. The post-tests will be conducted 3 days after the pre-test without any messages being requested from the mothers in the control group.
Study NCT06744881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAPA-IVM
Description: On days 2-4 of the menstrual cycle, after patients have consented to CAPA-IVM, they will undergo oocyte aspiration anytime thereafter but no later than day 6 of the cycle. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 or day 5 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transfer
Study NCT06746948 — intervention group
Intervention type: OTHER
Intervention: dyadic psychological distress
Description: There is no intervention among the cross-sectional study.
Study NCT06746493 — intervention group
Intervention type: OTHER
Intervention: Rehabilitation
Description: People after a stroke participated in a standard rehabilitation process carried out at the neurological rehabilitation department.
Study NCT06750302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methoxyflurane - Penthrox
Description: 3ml
Study NCT06750302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline + one drop of methoxyflurane
Study NCT06751108 — intervention group
Intervention type: DRUG
Intervention: Corticosteroids (CS)
Description: Concomitant use of immune checkpoint inhibitors and corticosteroids
Study NCT06751108 — intervention group
Intervention type: DRUG
Intervention: Immune Checkpoint Inhibitors
Description: Non-concomitant use of corticosteroids
Study NCT06749314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Endoscopic - Unilateral Laminotomy for Bilateral Decompression
Description: The LE-ULBD: Lumbar Endoscopic - Unilateral Laminotomy for Bilateral Decompression is a single portal through lamina with instrument to decompression both side of the spinal canal, giving strength of preserve facet joint, preserve spinal musculature, mitigate the risk of adjacent fusion and lesser bleeding
Study NCT06751355 — intervention group
Intervention type: DEVICE
Intervention: SkinScan3D camera
Description: The SkinScan3D (SS3D) is a portable, battery-powered imaging prototype which can successfully achieve all-focus, 3D images using low-cost, off-the-shelf components.
Study NCT06609928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pheresis
Description: Undergo apheresis
Study NCT06750068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed space maintainer
Description: Digitally fabricated #d printed space maintainer
Study NCT06609928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT06617169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNPR-101-PCTA-177Lu
Description: MNPR-101-PCTA-177Lu administered intravenously over approximately 20 minutes, followed by a normal saline flush. Dosing will occur on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1.
Study NCT06629701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External support for vein grafts
Description: Group A will consist of a group of patients who will be sutured with external support for vein grafts.
Study NCT06629324 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Bone Marrow Mononuclear Cell Transfusion
Description: Bone marrow was collected under general anesthesia from both anterior superior iliac crests, taking 15-20 minutes, with a maximum volume of 350 mL for older children. Mononuclear cells were isolated using Ficoll density gradient centrifugation and prepared for infusion. The infusion, performed in the L4-L5 spinal space, lasted about 30 minutes at a rate of 20 mL per hour. Cerebrospinal fluid (CSF) was withdrawn before infusion, with the amount based on the child's weight. Patients received Rocephin for infection prevention and pain relief with alternating doses of Ibuprofen and Efferalgan for 2 days post-procedure. Seduxen was given once on the first night after bone marrow collection.
Study NCT06629324 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Bone Marrow Mononuclear Cell Transfusion
Description: Bone marrow was collected under general anesthesia from both anterior superior iliac crests, taking 15-20 minutes, with a maximum volume of 350 mL for older children. Mononuclear cells were isolated using Ficoll density gradient centrifugation and prepared for infusion. The infusion, performed in the L4-L5 spinal space, lasted about 30 minutes at a rate of 20 mL per hour. Cerebrospinal fluid (CSF) was withdrawn before infusion, with the amount based on the child's weight. Patients received Rocephin for infection prevention and pain relief with alternating doses of Ibuprofen and Efferalgan for 2 days post-procedure. Seduxen was given once on the first night after bone marrow collection.